Literature DB >> 22318161

Significance of the microbiome in obstructive lung disease.

Meilan K Han1, Yvonne J Huang, John J Lipuma, Homer A Boushey, Richard C Boucher, William O Cookson, Jeffrey L Curtis, John Erb-Downward, Susan V Lynch, Sanjay Sethi, Galen B Toews, Vincent B Young, Matthew C Wolfgang, Gary B Huffnagle, Fernando J Martinez.   

Abstract

The composition of the lung microbiome contributes to both health and disease, including obstructive lung disease. Because it has been estimated that over 70% of the bacterial species on body surfaces cannot be cultured by currently available techniques, traditional culture techniques are no longer the gold standard for microbial investigation. Advanced techniques that identify bacterial sequences, including the 16S ribosomal RNA gene, have provided new insights into the depth and breadth of microbiota present both in the diseased and normal lung. In asthma, the composition of the microbiome of the lung and gut during early childhood development may play a key role in the development of asthma, while specific airway microbiota are associated with chronic asthma in adults. Early bacterial stimulation appears to reduce asthma susceptibility by helping the immune system develop lifelong tolerance to innocuous antigens. By contrast, perturbations in the microbiome from antibiotic use may increase the risk for asthma development. In chronic obstructive pulmonary disease, bacterial colonisation has been associated with a chronic bronchitic phenotype, increased risk of exacerbations, and accelerated loss of lung function. In cystic fibrosis, studies utilising culture-independent methods have identified associations between decreased bacterial community diversity and reduced lung function; colonisation with Pseudomonas aeruginosa has been associated with the presence of certain CFTR mutations. Genomic analysis of the lung microbiome is a young field, but has the potential to define the relationship between lung microbiome composition and disease course. Whether we can manipulate bacterial communities to improve clinical outcomes remains to be seen.

Entities:  

Mesh:

Year:  2012        PMID: 22318161      PMCID: PMC3578398          DOI: 10.1136/thoraxjnl-2011-201183

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  90 in total

Review 1.  Pyrosequencing sheds light on DNA sequencing.

Authors:  M Ronaghi
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

2.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  J Kirk Harris; Mary Ann De Groote; Scott D Sagel; Edith T Zemanick; Robert Kapsner; Churee Penvari; Heidi Kaess; Robin R Deterding; Frank J Accurso; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

3.  Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.

Authors:  G B Rogers; M P Carroll; D J Serisier; P M Hockey; G Jones; V Kehagia; G J Connett; K D Bruce
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 4.  Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; MeiLan K Han; Kevin Flaherty; Jeffrey Curtis
Journal:  Expert Rev Anti Infect Ther       Date:  2006-02       Impact factor: 5.091

Review 5.  The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research.

Authors:  Jeffrey L Curtis; Christine M Freeman; James C Hogg
Journal:  Proc Am Thorac Soc       Date:  2007-10-01

6.  At least 1 in 20 16S rRNA sequence records currently held in public repositories is estimated to contain substantial anomalies.

Authors:  Kevin E Ashelford; Nadia A Chuzhanova; John C Fry; Antonia J Jones; Andrew J Weightman
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

7.  Analysis of the lung microbiome in the "healthy" smoker and in COPD.

Authors:  John R Erb-Downward; Deborah L Thompson; Meilan K Han; Christine M Freeman; Lisa McCloskey; Lindsay A Schmidt; Vincent B Young; Galen B Toews; Jeffrey L Curtis; Baskaran Sundaram; Fernando J Martinez; Gary B Huffnagle
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

8.  Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities.

Authors:  Christopher J van der Gast; Alan W Walker; Franziska A Stressmann; Geraint B Rogers; Paul Scott; Thomas W Daniels; Mary P Carroll; Julian Parkhill; Kenneth D Bruce
Journal:  ISME J       Date:  2010-12-09       Impact factor: 10.302

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine.

Authors:  Ivaylo I Ivanov; Rosa de Llanos Frutos; Nicolas Manel; Keiji Yoshinaga; Daniel B Rifkin; R Balfour Sartor; B Brett Finlay; Dan R Littman
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

View more
  96 in total

Review 1.  Microbiome of the paranasal sinuses: Update and literature review.

Authors:  Jivianne T Lee; Daniel N Frank; Vijay Ramakrishnan
Journal:  Am J Rhinol Allergy       Date:  2016 Jan-Feb       Impact factor: 2.467

Review 2.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

3.  Human rhinovirus, wheezing illness, and the primary prevention of childhood asthma.

Authors:  Carlos A Camargo
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

4.  The bronchial microbiome and asthma phenotypes.

Authors:  Yvonne J Huang; Homer A Boushey
Journal:  Am J Respir Crit Care Med       Date:  2013-11-15       Impact factor: 21.405

5.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

Review 6.  The relationships between environmental bacterial exposure, airway bacterial colonization, and asthma.

Authors:  Avraham Beigelman; George M Weinstock; Leonard B Bacharier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-04

7.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

Authors:  MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2014-04-21       Impact factor: 30.700

Review 8.  Early-life viral infections and the development of asthma: a target for asthma prevention?

Authors:  Daniel J Jackson
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-04

9.  The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report.

Authors:  Yvonne J Huang; Emily S Charlson; Ronald G Collman; Sandra Colombini-Hatch; Fernando D Martinez; Robert M Senior
Journal:  Am J Respir Crit Care Med       Date:  2013-06-15       Impact factor: 21.405

Review 10.  Is asthma an infectious disease? New evidence.

Authors:  T Prescott Atkinson
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.